Turkish Journal of Medical Sciences
Volume 35

Number 2

Article 6

1-1-2005

Effects of Oral Granisetron Treatment on Uremic Pruritus
BÜLENT TOKGÖZ
ALPER ATA
MURAT SİPAHİOĞLU
OKTAY OYMAK
SERAP UTAŞ

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
TOKGÖZ, BÜLENT; ATA, ALPER; SİPAHİOĞLU, MURAT; OYMAK, OKTAY; UTAŞ, SERAP; and UTAŞ, CENGİZ
(2005) "Effects of Oral Granisetron Treatment on Uremic Pruritus," Turkish Journal of Medical Sciences:
Vol. 35: No. 2, Article 6. Available at: https://journals.tubitak.gov.tr/medical/vol35/iss2/6

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Effects of Oral Granisetron Treatment on Uremic Pruritus
Authors
BÜLENT TOKGÖZ, ALPER ATA, MURAT SİPAHİOĞLU, OKTAY OYMAK, SERAP UTAŞ, and CENGİZ UTAŞ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol35/iss2/6

Turk J Med Sci
35 (2005) 93-97
© TÜB‹TAK

CLINICAL INVESTIGATIONS

Effects of Oral Granisetron Treatment on Uremic Pruritus

Bülent TOKGÖZ1, Alper ATA1, Murat S‹PAH‹O⁄LU1, Oktay OYMAK1, Serap UTAfi2, Cengiz UTAfi1
1

Department of Nephrology, Faculty of Medicine, Erciyes University, Kayseri - Turkey

2

Department of Dermatology, Faculty of Medicine, Erciyes University, Kayseri - Turkey

Received: April 19, 2004

Abstract: The present study aimed to investigate the efficacy, safety, and tolerability of orally administered granisetron, a 5-HT3
receptor antagonist, and its possible effect on serum histamine and serotonin levels in uremic pruritic patients who have not yet
undergone dialysis.
Fourteen patients with newly diagnosed end-stage renal disease were asked to complete a questionnaire about pruritus, and
histamine, serotonin, PTH and cortisol levels were measured on days 0, 7 and 14. Granisetron (1 mg) was administered twice daily
for 2 weeks.
Plasma histamine levels were found to be up to 7 times higher in all patients and they did not change significantly during the study.
Serum serotonin levels decreased significantly on days 7 and 14 of the study in women compared with men (P < 0.05). There was
no significant change in the histamine X serotonin values except for the decrease in men on day 14 of the study (P < 0.05). Pruritus
scores decreased at the end of the study compared with the beginning but this was not statistically significant. However, the decrease
in pruritus scores in women on days 7 and 14 vas statistically significant (P < 0.05).
Pruritic uremic patients with end-stage renal disease and have not been undergone any of the renal replacement therapies, were
found to have markedly elevated plasma histamine levels. Granisetron was found to be effective particularly in newly diagnosed
female uremic patients.
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Introduction

Materials and Methods

Ondansetron, a selective inhibitor of 5hydroxytryptamine3 (5-HT3) receptors in the central and
peripheral neural systems, has been used in some pruritic
patients due to cholestasis of various etiologies and in
uremic pruritic patients on peritoneal dialysis with
satisfactory results (1-3). To the best of our knowledge
the effects of 5HT3 receptor antagonists have not been
investigated in patients who have not received any dialytic
treatment. Our aim was to investigate the action
mechanism of orally administered granisetron, a 5-HT3
receptor antagonist, on pruritus among uremic patients
who had not undergone any renal replacement therapy but
were awaiting maturation of an arteriovenous fistula or a
newly placed peritoneal dialysis catheter. Additionally, the
efficacy, safety, and tolerability of orally administered
granisetron were also evaluated and possible effects on
histamine and serotonin levels were tested.

Fourteen predialytic uremic patients were included in
the study. Out of the 14, diabetes mellitus was diagnosed
in 3 (21.42%), chronic glomerulonephritis in 1 (7.14%),
and obstructive uropathy in 1 (7.14%) and no underlying
disease was found in the remaining 9 (64.28%).
The severity of pruritus was measured using a
method proposed by Duo (4) and modified by Mettang et
al. (5) and afterwards by Balaskas et al. (6). This method
is based on criteria such as scratching, severity, frequency
and distribution of pruritus, number of sleeping hours
and frequency of waking up during the night because of
itching. Pruritus was graded according to the total points
for each patient as mild “1-16”, moderate “17-32”, and
severe “33-48”.
Biochemical parameters, plasma histamine, serum
serotonin, PTH and cortisol levels were measured on days
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0, 7 and 14. The patients were treated with granisetron
(Kytril ® tablet) 1 mg twice daily for a mean duration of
2 weeks. All statistical values were analyzed by a
nonparametric method. The differences between levels of
histamine, serotonin, ‘histamine X serotonin’ products,
PTH and cortisol were analyzed using the Wilcoxon test.
The Spearman nonparametric correlation test was used
for analyzing the correlations between all parameters. P
less than 0.05 was considered significant.

Results

between xerosis and age, sex, hematological and
biochemical parameters, histamine, serotonin, ‘histamine X
serotonin’ products and cortisol levels. There was a weak
correlation between PTH levels and xerosis (P: 0.047).
Mean pruritus scores were 26.00, 22.50 and 15.00 in the
patients with mild xerosis; 30.20, 25.00 and 13.60 in the
patients with moderate xerosis; and 28.42, 23.42 and
13.71 in the patients with severe xerosis on days 0, 7 and
14, respectively. There was a weak positive correlation
between the presence and severity of pruritus and the
severity of xerosis (P: 0.374, r: 0.258).

Fourteen patients (5 male and 9 female) with a mean
age of 49.45 ± 15.1 years (range from 18 to 74 years)
were evaluated. The severity of xerosis did not change in
any patients during the study. There was no correlation

There was no statistically significant relationship
between the sexes according to histamine, PTH, cortisol
levels, or other hematological or biochemical parameters
(Table 1).

Table 1. Biochemical parameters throughout the study.
N
Serotonin day 0
Serotonin day 7
Serotonin day 14
Histamine day 0
Histamine day 7
Histamine day 14
Histamine X Serotonin day 0
Histamine X Serotonin day 7
Histamine X Serotonin day 14
PTH day 0
PTH day 7
PTH day 14
Cortisol day 0
Cortisol day 7
Cortisol day 14

* P < 0.05

94

Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female

5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9
5
9

Mean ± SD
143.01 ± 27.71
164.82 ± 24.58
162.55 ± 35.13
143.56 ± 21.18 *
157.53 ± 26.51
159.72 ± 21.66 *
4.10 ± 0.77
4.89 ± 1.39
4.35 ± 0.96
4.98 ± 0.82
4.40 ± 1.09
4.41 ± 0.75
573.17 ± 62.77
795.51 ± 206.12
695.33 ± 180.27
709.28 ± 128.01
681.31 ± 151.79
708.19 ± 172.28
255.0 ± 371.9
428.1 ± 332.6
90.2 ± 54.9
453.4 ± 378.5
107.4 ± 46.6
383.6 ± 334.6
15.24 ± 9.64
12.78 ± 2.71
17.17 ± 9.65
13.57 ± 4.95
14.11 ± 1.69
11.06 ± 2.41

IQR
41.00
44.53
68.64
43.12
42.01
31.08
1.45
1.57
1.46
0.86
2.01
1.02
119.51
331.27
323.11
136.96
299.51
344.64
458.5
470.5
99.5
504.5
92.5
437.0
12.94
4.83
13.06
5.51
3.10
3.95
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Plasma histamine levels were markedly increased in all
patients, up to 7 times higher than the upper normal
limit. Histamine levels did not change significantly during
the study. Serum serotonin levels were not increased
above normal values but presented fluctuations as in the
normal healthy population. Serum serotonin levels were
decreased significantly on days 7 and 14 in women
compared to men (P < 0.05). We calculated the product
‘histamine X serotonin’ in all patients and there was no
significant change in these values except for the increase
in men on day 14, which was statistically significant (P <
0.05).

severity of pruritus (9). The results of the present study
are independent of the dialysis, because all patients were
newly diagnosed and had not chosen the type of renal
replacement therapy.

PTH and cortisol levels were measured in all patients.
PTH levels showed fluctuations and increased up to 18
times higher than upper values. PTH levels were
decreased on days 7 and 14 of the study in both sexes but
this decrease was not statistically significant. There was
no relationship between PTH levels and pruritus scores.
There was also no relationship between cortisol levels and
pruritus. An average negative correlation was found
between mean cortisol levels and pruritus score on day 7
(P: 0.028, r: 0.028). Cortisol levels were decreased on
days 7 and 14 but these decreases were not statistically
significant.

It was reported that plasma histamine levels were
increased in uremic patients (5,11,14,15). Some
investigators reported a positive correlation between
plasma histamine levels and pruritus (15,16), but others
did not (11,17). In our study plasma histamine levels
were noticeably increased but this was not correlated
with the severity of pruritus.

Pruritus scores were decreased at the end of the
study compared to the beginning but this decrease was
not statistically significant. However, the decreases in
pruritus scores in women on days 7 and 14 were
statistically significant (P < 0.05) (Table 2).

Discussion
Pruritus and xerosis are the most common cutaneous
manifestations in uremic patients (7-,8). The etiology of
uremic pruritus remains unclear, and no therapy to date
has been reliably effective (9,10). A longer time on
dialysis may cause an increase in the prevalence and

Table 2. Pruritus scores during treatment.
PRURITUS SCORE

Before treatment
1st week
2nd week

Mean ± SD

Range

P

28.4 ± 5
23.6 ± 3.6
14.1 ± 3.4

16-36
17-30
8-20

> 0.05
> 0.05

It is well known that xerosis may contribute to
pruritus (6,11,12). It has been found that pruritic
patients had lower water content in the stratum corneum
layer of the skin than nonpruritics (12,13). In our study
the water content of the stratum corneum was not
measured but the severity of xerosis according to the
physical examination was positively correlated with the
pruritus scores.

Balaskas et al. reported that the measurement of
serum serotonin levels revealed large fluctuations in
pruritic patients as in healthy subjects (3). They also
found that there was a difference between normal values
and those of patients, but it was not statistically
significant. In our study serum serotonin levels showed
fluctuations but stayed within the normal ranges (3).
Balaskas et al. also reported that there was a greater
difference between 2 groups of patients (CAPD and HD
patients) when they calculated the ‘histamine X serotonin’
products (3). Because pruritus is possibly multifactorial
we also tried to calculate the product of 2 possible
mediators, histamine and serotonin, like the previous
investigators. However, we could not find a relationship
between these products and other parameters. We found
fluctuating levels of serotonin but they were all within
normal ranges. Fluctuations of serum serotonin levels
may affect the severity of pruritus.
Secondary hyperparathyroidism and increased
product of calcium and phosphorus (Ca X P) may play
roles in the pathogenesis of pruritus in uremic patients as
well (18). Chou et al. reported that pruritus in patients
with secondary hyperparathyroidism can be reduced by
parathyroidectomy and also they found the high levels of
Ca X P was the only factor that seemed to affect the
postoperative extent of pruritus (18). In our study there
was a weak correlation between PTH levels and xerosis
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but not with pruritus scores, confirming the previous
study.
All uremic patients are under severe mental stress at
the beginning of the disease (19). It has been shown that
experimentally induced mental stress activates the
psychoneuroendocrine systems and skin responses
established as itch and flare (20). Basal and urinary
cortisol levels were found to be increased in these
patients. Hypercortisolemic state causes pruritus (21).
We measured the basal cortisol levels depending on these
data, but we did not find a correlation between basal
cortisol levels and pruritus scores except for a positive
correlation on day 7 of the study. Almost all of our
patients had normal basal cortisol levels and cortisol levels
were not related to the presence or severity of the
pruritus.
Balaskas et al. administered ondansetron for the
management of uremic pruritus in CAPD patients with
satisfactory results (3). Based on the above findings we
administered granisetron for the same purpose. Severity
of pruritus decreased progressively, especially in women,
but had not disappeared totally at the end of the second
week of treatment. No side effects or complications were
observed. Levels of histamine and serotonin were not
decreased significantly at the end of our study, in contrast
to the study by Balaskas et al.

mediators, confirming the results reported by Weisshaar
et al. (22). Weisshaar et al. demonstrated that
tropisetron as a 5-HT3 receptor antagonist did not affect
histamine-induced itch but has a measurable effect on
serotonin-induced itch. We think that the local release of
histamine at the tissue level presumably causes pruritus,
and plasma levels would be only a crude indicator of local
tissue reactions.
In conclusion, pruritic uremic patients who had newly
diagnosed end-stage renal disease and had not undergone
any renal replacement therapy, were found to have
markedly elevated plasma histamine levels and were more
xerotic. None of the parameters that changed during the
study can explain the improvement in pruritic symptoms.
Serotonin levels did not elevate but showed fluctuations.
However, we know that the number of patients was low
in our study and so new studies have to be planned with
larger groups.
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